Compare Synchrony Financial (SYF) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs Viatris Inc — how do they compare? Synchrony Financial trades at $71.7 (market cap $24.69B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Synchrony Financial is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| SYF | VTRS | |
|---|---|---|
Market Cap | $24.69B | $19.79B |
Sector | Financials | Health |
52-Week High | $88.47 | $17.39 |
52-Week Low | $63.78 | $8.74 |
Dividend Yield | 1.63% | 2.83% |
Enterprise Value | — | $32.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $73.41, down 0.29% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a net income margin of 24.06% and ROE of 22.98%, supported by consistent earnings beats in recent quarters. Recent Q2 2026 results highlighted record purchase volume and a raised EPS outlook, though cash flow trends indicate a net outflow projection for 2026. Analyst consensus remains strongly bullish with a $86.38 price target.
The outlook for SYF is positive based on fundamental strength and analyst confidence, but near-term technical pressure and macroeconomic sensitivity pose risks. Investment appeal lies in its low P/E of 7.6 and dividend yield, though investors should monitor credit quality and interest rate impacts given its consumer lending focus.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
